Form

Equifax to Expand I-9 Anywhere® with New Virtual Option

Retrieved on: 
Thursday, October 26, 2023
Documentation, I-9, Equifax Workforce Solutions, U.S. Department of Defense Strategy for Operating in Cyberspace, Form, United States Department of Homeland Security, NYSE, Equifax, Employment, DHS, Online shopping

ATLANTA, Oct. 26, 2023 /PRNewswire/ -- Equifax® (NYSE: EFX) is addressing the growing demand for flexible, remote onboarding services by offering a virtual component of its award-winning I-9 Anywhere® solution. This enhancement will make it easier for eligible employers to streamline their onboarding processes and enhance new hire experiences. The new capability will align with the recent U.S. Department of Homeland Security (DHS) announcement enabling employers who participate in E-Verify and are in good standing to have the option to conduct Form I-9 verification electronically and with a live video call interaction.

Key Points: 
  • The new I-9 Anywhere virtual component will offer employers a fully outsourced I-9 solution – regardless of where their new hires are located.
  • "The new I-9 Anywhere virtual option is one more way we are helping businesses simplify complex HR processes," said Lisa Chall, Vice President of Onboarding & Talent Solutions at Equifax Workforce Solutions.
  • The virtual option will complement the existing I-9 Anywhere in-person process.
  • Equifax Workforce Solutions expects to launch the new I-9 Anywhere virtual option prior to the end of the year, and remains committed to driving innovation and expanding its leading onboarding solution suite.

EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Retrieved on: 
Thursday, October 26, 2023
Therapy, Cyprus Securities and Exchange Commission, Exercise, KREO, SVB Securities, American depositary receipt, Code, State Street, Sale, Telephone, Form, European Parliament, Patient, CD, Varick Street, CEST, Research, Application, 2nd Floor, ADS, European, Note, AMF, Council, Morgan Stanley, UC, Private, Attention, CIR, The Heights, Prospectus, Document, KC, Commercial code, Security (finance), Cryptocurrency, Pharmaceutical industry, Abivax, EU, Euronext Paris

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Key Points: 
  • Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
    The issuer is solely responsible for the content of this announcement.
  • Offering”) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement”, and together, the “Global Offering”).
  • The Company’s ordinary shares are listed on the regulated market of Euronext Paris (“Euronext Paris”) under the symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 

Retrieved on: 
Thursday, October 26, 2023
Compartment, Therapy, Chapter Three, Exercise, KREO, Central bank, SVB Securities, American depositary receipt, Code, State Street, Sale, Telephone, Form, Patient, CD, Varick Street, CEST, Research, 2nd Floor, ADS, Note, Chapter Five, AMF, Morgan Stanley, UC, ISIN, Private, Attention, CIR, European Central Bank, The Heights, Risk, Prospectus, Document, KC, Commercial code, Security (finance), Cryptocurrency, Pharmaceutical industry, Euronext Paris

Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Key Points: 
  • Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).
  • The Global Offering is expected to close on October 24, 2023, subject to the satisfaction of customary closing conditions.
  • The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October 20, 2023 under the ticker symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Tandem Diabetes Care, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 7, 2023 – (NASDAQ: TNDM)

Retrieved on: 
Wednesday, October 25, 2023
Tandem, Complaint, Growth, Inc., COVID, Fraud, Tandem Diabetes Care, Form, NEXT, Holding company, Security (finance)

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022.

Key Points: 
  • ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022.
  • On November 2, 2022, Tandem closed at $51.34; however, on November 3, 2022 Tandem closed at $35.72 – a one-day decline of 30.4%.
  • DEADLINE: November 7, 2023 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Staffing 360 Solutions Receives Nasdaq Notification of Potential Delisting for Non-Compliance with Listing Rule 5250(c)(1)

Retrieved on: 
Tuesday, October 24, 2023
United Kingdom, Security (finance), Form, Acquisition, Form 10-Q, Panel, Hearing, Calendar, Letter

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Staffing 360 Solutions, Inc. ( Nasdaq: STAF ) (“Staffing 360 Solutions” or the “Company”), a company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, today reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended June 30, 2023 with the Securities and Exchange Commission (“SEC”).

Key Points: 
  • NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Staffing 360 Solutions, Inc. ( Nasdaq: STAF ) (“Staffing 360 Solutions” or the “Company”), a company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, today reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended June 30, 2023 with the Securities and Exchange Commission (“SEC”).
  • In a separate letter, the Nasdaq Listing Qualifications Department recognized the filing of the Company’s Quarterly Report on Form 10-Q for the period ended April 1, 2023 on October 16, 2023, and notified the Company it had regained compliance with the Nasdaq Listing Rule with respect to the Form 10-Q for the period ended April 1, 2023.
  • In connection with the hearing request, the Company will request that the stay be extended through the hearing and the expiration of any additional extension period granted by the Panel following the hearing.
  • Staffing 360 Solutions expects to file the outstanding Form 10-Q for the quarter ended June 30, 2023 in the coming weeks.

AppTech Payments Corp. Announces Pricing of $3.5 Million Registered Direct Offering

Retrieved on: 
Tuesday, October 24, 2023
Titan, Sale, Enterprise file synchronization and sharing, Security (finance), Telephone, Fintech, World Trade Center, Form, Bangladesh Securities and Exchange Commission, TowerBrook Capital Partners, Prospectus, S-3

The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $2.10.

Key Points: 
  • The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $2.10.
  • Titan Partners Group, a division of American Capital Partners, is acting as sole placement agent for the offering.
  • The offering is expected to close on or about October 26, 2023, subject to the satisfaction of customary closing conditions.
  • The shares of common stock and warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No.

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Retrieved on: 
Tuesday, October 24, 2023
TenX, READ, Suite, Food, Medication, Lexington Avenue, Auxiliary routes of Arkansas Highway 18, SPAC, Sale, Form, Acquisition, ONCE, CTCL, Patient, Person, Commerce, PD-1, Newbridge, Non-Hodgkin lymphoma, FDA, Biologics license application, Regulation of tobacco by the U.S. Food and Drug Administration, Prospectus, Peripheral T-cell lymphoma, Annual report, BLA, Security (finance), Pharmaceutical industry, Bank, Cryptocurrency, Citius, Altius, Fortius

CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition (“TenX”) (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Key Points: 
  • The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”).
  • Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology.
  • “We are very pleased to announce the proposed merger with Citius Oncology,” said Mr. Xiaofeng Yuan, Chairman and CEO of TenX.
  • In the transaction, all shares of Citius Pharma’s wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.

DevvStream Reaches Key Milestone Toward Nasdaq Listing

Retrieved on: 
Tuesday, October 24, 2023
Combination, Register, Public Company Accounting Oversight Board, Security (finance), Business analyst, Form, Carbon, Transaction, Bank statement, Registration statement, FIAC, CBOE, FSE, DESG, Culture

The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing.

Key Points: 
  • The Transaction values DevvStream at an implied enterprise value of approximately $212.8 million, representing an equity value of C$2.16 per DevvStream subordinate voting share prior to closing.
  • The Business Combination is expected to be completed by early Q1 2024, subject to the satisfaction of closing conditions under the Business Combination Agreement.
  • Learn more about the Company’s progress by joining a live webinar presented by DevvStream and Focus Impact on Thursday, October 26th at 9:30am PT / 12:30pm ET.
  • “Since DevvStream and Focus Impact agreed to merge, the transaction has proceeded smoothly and efficiently,” said Sunny Trinh, CEO of DevvStream.

TANDEM ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, October 24, 2023
Complaint, Person, Telephone, Form, Court, P.C, Tandem, Growth, COVID, District court, Cryptocurrency

Investors have until November 7, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 7, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • The complaint alleges that defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022.
  • On November 2, 2022, Tandem closed at $51.34; however, on November 3, 2022, Tandem closed at $35.72 – a one-day decline of 30.4%.

Nxu, Inc. Announces Closing of $3.0 Million Public Offering of Common Stock

Retrieved on: 
Monday, October 23, 2023
Sale, SEC filing, Security (finance), Park Avenue, EV, Telephone, Form S-1, Form, Attention, Prospectus

The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and other offering expenses, were approximately $3.0 million.

Key Points: 
  • The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and other offering expenses, were approximately $3.0 million.
  • Maxim Group LLC acted as the sole placement agent in connection with the offering.
  • The offering was conducted pursuant to the Company's registration statement on Form S-1, as amended, (File No.
  • A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov .